Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Pulmonary Hypertension, February 2025 Free Subscription Abstracts Retrieve all available abstracts of the following 162 articles: HTML format

Single Articles

1. TAN J, Cao X, Zheng R, Xie S, et al
   Celastrol Ameliorates Hypoxia-Induced Pulmonary Hypertension by Regulation of the PDE5-cGMP-PKG Signaling Pathway.
   Phytother Res. 2025 Jan 30. doi: 10.1002/ptr.8446.
   PubMed    
   Abstract available
   
   

2. ABDELKADER AEA, Ilonze OJ, Guglin M
   Dysfunctional Implantable Pulmonary Artery Sensor Device (CardioMEMS) in Group 2 Pulmonary Hypertension.
   JACC Case Rep. 2025;30:102801.
   PubMed    
   Abstract available
   
   

3. CHI E, Chandrasekara S, Keating DT
   Severe pulmonary arterial hypertension and cardiogenic shock in acute systemic lupus erythematosus.
   BMJ Case Rep. 2025;18:e262651.
   PubMed    
   Abstract available
   
   

4. KUMAR R, Nolan K, Kassa B, Chanana N, et al
   Monocytes and interstitial macrophages contribute to hypoxic pulmonary hypertension.
   J Clin Invest. 2025 Jan 30:e176865. doi: 10.1172/JCI176865.
   PubMed    
   Abstract available
   
   

5. WANG J, Guan L, Yu J, Ma B, et al
   Halofuginone prevents inflammation and proliferation of high-altitude pulmonary hypertension by inhibiting the TGF-beta1/Smad signaling pathway.
   Sci Rep. 2025;15:3619.
   PubMed    
   Abstract available
   
   

6. RIBEIRO JM, Santana AB, de Oliveira Marusso L, de Oliveira Marrafon DAF, et al
   Effectiveness and safety of the use of sodium nitrite in patients with hypertension and pulmonary hypertension: a scoping review.
   Naunyn Schmiedebergs Arch Pharmacol. 2025.
   PubMed    
   Abstract available
   
   

7. TORRES-ROJAS MB, Navarro-Vergara DI, Garcia-Cesar M, Acosta-Altamirano G, et al
   Right Heart Catheterization Accurately Diagnoses Pulmonary Hypertension in Patients With Interstitial Lung Disease: Results From a Long-Term Cohort Study.
   Pulm Circ. 2025;15:e70035.
   PubMed    
   Abstract available
   
   

8. PRADHAN A, Tyagi R, Sharma P, Bajpai J, et al
   Shifting Paradigms in the Management of Pulmonary Hypertension.
   Eur Cardiol. 2024;19:e25.
   PubMed    
   Abstract available
   
   

9. CHEN MQ, Wang A, Wan CX, Ruan BQ, et al
   Prognostic value of atherogenic index of plasma in pulmonary hypertension.
   Front Med (Lausanne). 2025;11:1490695.
   PubMed    
   Abstract available
   
   

10. LIU H, Liu S, Ma P, Ma L, et al
    Development and Evaluation of Aloperine-Loaded Nanostructured Lipid Carriers for the Treatment of Pulmonary Arterial Hypertension.
    Int J Nanomedicine. 2025;20:871-886.
    PubMed    
    Abstract available
    
    

11. WEI Z, Shao X, An Z, Chang Y, et al
    The impact of pulmonary hypertension on prognosis in moderate-to-severe mitral regurgitation patients treated with transcatheter edge-to-edge mitral valve repair: a comprehensive meta-analysis.
    Front Cardiovasc Med. 2025;11:1489674.
    PubMed    
    Abstract available
    
    

12. WANG F, Xiao W, Li J, Zhang Z, et al
    p16(INK4a) promoted progress of MCT induced pulmonary hypertension via maintaining redox balance and autophagy pathway.
    Biochem Biophys Res Commun. 2025;749:151385.
    PubMed    
    Abstract available
    
    

13. JAKUBOWSKI BR, Griffiths M, Goss KN
    The Role of Imaging in Pulmonary Vascular Disease: The Clinician's Perspective.
    Radiol Clin North Am. 2025;63:305-313.
    PubMed    
    Abstract available
    
    

14. AGIRLAR TRABZONLU T, Allen BD
    Role of Cardiovascular MR Imaging and MR Angiography in Patients with Pulmonary Vascular Disease.
    Radiol Clin North Am. 2025;63:279-291.
    PubMed    
    Abstract available
    
    

15. HAHN LD, Chung JH
    Imaging of Chronic Thromboembolic Pulmonary Hypertension.
    Radiol Clin North Am. 2025;63:223-234.
    PubMed    
    Abstract available
    
    

16. SRIDHAR S, Ebrahimzadeh S, Ahn H, Lee C, et al
    Imaging Approach to Pulmonary Hypertension.
    Radiol Clin North Am. 2025;63:193-205.
    PubMed    
    Abstract available
    
    

17. CONSING-GANGELHOFF M, Sharobim M, Bodnar C, Kanne JP, et al
    Pathology of Pulmonary Vascular Disease with Radiologic Correlation.
    Radiol Clin North Am. 2025;63:179-191.
    PubMed    
    Abstract available
    
    

18. LUCERO M, Lisk C, Cendali F, Swindle D, et al
    TARGETING LUNG HEME IRON BY AEROSOL HEMOPEXIN ADMINSTRATION IN SICKLE CELL DISEASE PULMONARY HYPERTENSION.
    Free Radic Biol Med. 2025 Jan 23:S0891-5849(25)00056.
    PubMed    
    Abstract available
    
    

19. KRONBERGER C, Mousavi RA, Ermolaev N, Willixhofer R, et al
    One-minute sit-to-stand test cut-offs for risk stratification based on six-minute walk test thresholds in pulmonary hypertension.
    Eur J Prev Cardiol. 2025 Jan 25:zwaf031. doi: 10.1093.
    PubMed    
    Abstract available
    
    

20. NAKAMURA K, Akagi S, Ejiri K, Taya S, et al
    Pathophysiology of Group 3 Pulmonary Hypertension Associated with Lung Diseases and/or Hypoxia.
    Int J Mol Sci. 2025;26:835.
    PubMed    
    Abstract available
    
    

21. ATTARIPOUR ESFAHANI S, Baba Ali N, Farina JM, Scalia IG, et al
    A Comprehensive Review of Artificial Intelligence (AI) Applications in Pulmonary Hypertension (PH).
    Medicina (Kaunas). 2025;61:85.
    PubMed    
    Abstract available
    
    

22. DRAGOI IT, Rezus C, Burlui AM, Bratoiu I, et al
    Multimodal Screening for Pulmonary Arterial Hypertension in Systemic Scleroderma: Current Methods and Future Directions.
    Medicina (Kaunas). 2024;61:19.
    PubMed    
    Abstract available
    
    

23. YANG S, Chen Q, Yang B
    Associations of cathepsins with pulmonary arterial hypertension mediated by circulating metabolites: A Mendelian randomization study.
    Medicine (Baltimore). 2025;104:e41405.
    PubMed    
    Abstract available
    
    

24. ALVES-SILVA JM, Zuzarte M, Marques C, Rodrigues T, et al
    1,8-Cineole reduces pulmonary vascular remodelling in pulmonary arterial hypertension by restoring intercellular communication and inhibiting angiogenesis.
    Phytomedicine. 2025;137:156334.
    PubMed    
    Abstract available
    
    

25. SHIGEFUKU R, Iwasa M, Yoshikawa K, Tanaka H, et al
    A rare case of idiopathic portal hypertension with portopulmonary hypertension occurred following splenectomy with a change in portal hemodynamics.
    Clin J Gastroenterol. 2025;18:130-136.
    PubMed    
    Abstract available
    
    

26. VIZZA CD, Klok R, Harley J, Small M, et al
    Clinical Characteristics and Treatment of Patients Diagnosed with Pulmonary Arterial Hypertension: A Real-World Study in the USA, Europe and Japan.
    Adv Ther. 2025;42:193-215.
    PubMed    
    Abstract available
    
    

27. GOOD SD, Lee JY, Johnson RE, Volkmann ER, et al
    A scoping review of the epidemiology of systemic sclerosis and its organ manifestations: 2018-2024.
    Curr Opin Rheumatol. 2025;37:103-112.
    PubMed    
    Abstract available
    
    

28. VILLANUEVA J, Wade J, Torres A, Hale G, et al
    Sotatercept: The First FDA-Approved Activin A Receptor IIA Inhibitor Used in the Management of Pulmonary Arterial Hypertension.
    Am J Cardiovasc Drugs. 2025;25:17-24.
    PubMed    
    Abstract available
    
    

29. RZEPKA MF, Raschzok S, Lee XA, Yazaki K, et al
    Inhibition of Myocardin-related Transcription Factor A Ameliorates Pathological Remodeling of the Pressure-loaded Right Ventricle.
    Am J Respir Cell Mol Biol. 2025;72:158-168.
    PubMed    
    Abstract available
    
    

30. DAI J, Liu T, Zhang H, Sun X, et al
    Fragmented QRS complex could predict all-cause mortality in patients with connective tissue disease-associated pulmonary arterial hypertension.
    Rheumatology (Oxford). 2025;64:789-797.
    PubMed    
    Abstract available
    
    

31. VEZINA FA, Bouchard PA, Breton-Gagnon E, Dion G, et al
    Automated O(2) Titration Alone or With High-Flow Nasal Cannula During Walking Exercise in Chronic Lung Diseases.
    Respir Care. 2023;69:1-14.
    PubMed    
    Abstract available
    
    

32. COLALILLO A, Pellicano C, Ananyeva LP, Hachulla E, et al
    Tricuspid Annular Plane Systolic Excursion/Systolic Pulmonary Artery Pressure Ratio and Cardiorenal Syndrome Type 2 in the Systemic Sclerosis EUSTAR Cohort.
    Arthritis Care Res (Hoboken). 2025;77:257-265.
    PubMed    
    Abstract available
    
    

33. WANG J, Xuan B, Song B, Wang T, et al
    MTMR7 attenuates the proliferation and migration of pulmonary arterial smooth muscle cells in pulmonary hypertension by suppressing ERK/STAT3 signaling.
    Mol Cell Biochem. 2025 Feb 7. doi: 10.1007/s11010-025-05217.
    PubMed    
    Abstract available
    
    

34. RAMANAND P, Indic P, Gentle SJ, Ambalavanan N, et al
    Detection of pulmonary hypertension in preterm infants with bronchopulmonary dysplasia using oxygen saturation data.
    Pediatr Res. 2025 Feb 6. doi: 10.1038/s41390-025-03891.
    PubMed    
    Abstract available
    
    

35. YAO X, Cai X, Zhang S, Yang Y, et al
    Mendelian randomization study of serum uric acid levels and urate-lowering drugs on pulmonary arterial hypertension outcomes.
    Sci Rep. 2025;15:4460.
    PubMed    
    Abstract available
    
    

36. BAI J, Gao D, Mei J, Yuan H, et al
    Exonic CircGUCY1A2 Inhibits Pulmonary Artery Smooth Muscle Cells Phenotypic Switching Via Regulating O-glycosylation of COL3A1 in Pulmonary Hypertension.
    Eur J Pharmacol. 2025 Feb 4:177328. doi: 10.1016/j.ejphar.2025.177328.
    PubMed    
    Abstract available
    
    

37. DIRICKX A, Levy M, Mellul K, Coignard M, et al
    Infants With a Congenital Diaphragmatic Hernia Had Favourable Pulmonary Hypertension Outcomes at 1 Year of Age.
    Acta Paediatr. 2025 Feb 6. doi: 10.1111/apa.70019.
    PubMed    
    Abstract available
    
    

38. DUFLOU J
    Rare but relevant: The injection of tablet preparations and pulmonary hypertension.
    Addiction. 2025 Feb 6. doi: 10.1111/add.70012.
    PubMed    
    Abstract available
    
    

39. GONG J, Li H, Cui X, Yan Y, et al
    Tianlong Kechuanling Decoction Attenuates Pulmonary Hypertension by Inhibiting Endothelial-to-Mesenchymal Transition.
    J Ethnopharmacol. 2025 Feb 3:119395. doi: 10.1016/j.jep.2025.119395.
    PubMed    
    Abstract available
    
    

40. PENTIKAINEN M, Simonen P, Leskela P, Harju T, et al
    Treatment pathways in Finnish patients with pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH).
    Pulm Circ. 2025;15:e12440.
    PubMed    
    Abstract available
    
    

41. RUBIN LJ
    Pulmonary Hypertension: A Personal Journey.
    Pulm Circ. 2025;15:e70047.
    PubMed    
    
    
    

42. DHANANI Z, Nicholson MJ, Gayen S
    Revised Precapillary Pulmonary Hypertension Criteria and Their Prognostic Value in IPF Transplant Waitlist Survival.
    Pulm Circ. 2025;15:e70046.
    PubMed    
    Abstract available
    
    

43. XIE X, Wang Y, Tian S, Cao D, et al
    Prognostic and Diagnostic Value of Platelet Distribution Width in COPD Patients with Pulmonary Hypertension: A Retrospective Study.
    Biotechnol Appl Biochem. 2025 Feb 3. doi: 10.1002/bab.2723.
    PubMed    
    Abstract available
    
    

44. WITTIG C, Konig JM, Pan X, Aman J, et al
    Shear stress unveils patient-specific transcriptional signatures in PAH: Towards personalized molecular diagnostics.
    Theranostics. 2025;15:1589-1605.
    PubMed    
    Abstract available
    
    

45. MA H, Xu F, Liu L, Kong H, et al
    Prognosis of pulmonary hypertension in patients with hypertrophic cardiomyopathy: A multicenter propensity score matching study.
    Int J Cardiol Heart Vasc. 2025;56:101605.
    PubMed    
    Abstract available
    
    

46. OGUZ M, Yilmaz I, Erdem A, Imre G, et al
    Dicrotic notch index in pulmonary hypertension: correlation with hemodynamic, echocardiographic and clinical parameters.
    Postepy Kardiol Interwencyjnej. 2024;20:449-454.
    PubMed    
    Abstract available
    
    

47. ITO S, Yoshitani K, Fukushima S, Matsuda H, et al
    Effect of Preoperative Pulmonary Hypertension on the Course of Right Ventricular Function: A Three-dimensional Echocardiographic Study in Valvular Surgery Patients.
    J Cardiovasc Echogr. 2024;34:170-178.
    PubMed    
    Abstract available
    
    

48. GUO L, Khobragade N, Kieu S, Ilyas S, et al
    Development and Evaluation of a Deep Learning-Based Pulmonary Hypertension Screening Algorithm Using a Digital Stethoscope.
    J Am Heart Assoc. 2025;14:e036882.
    PubMed    
    Abstract available
    
    

49. ALBULUSHI A, Al-Asmi S, Al-Abri M, Al-Farhan H, et al
    Elevated Lp(a) and its association with cardiac fibrosis in group II pulmonary hypertension patients.
    Future Cardiol. 2025 Feb 2:1-8. doi: 10.1080/14796678.2025.2460909.
    PubMed    
    Abstract available
    
    

50. FUJIWARA T, Ishii S, Minatsuki S, Hatano M, et al
    Exploring Novel Therapeutics for Pulmonary Arterial Hypertension.
    Int Heart J. 2025;66:3-12.
    PubMed    
    Abstract available
    
    

51. GELFMAN DM
    Diagnosis: Pulmonary Hypertension. Next Steps.
    Am J Med. 2025 Jan 30:S0002-9343(25)00060-9. doi: 10.1016/j.amjmed.2025.
    PubMed    
    Abstract available
    
    

52. PILARD CM, Cardouat G, Gauthereau I, Gassiat L, et al
    Celastrol has beneficial effects on pulmonary hypertension associated with bronchopulmonary dysplasia: Preclinical study outcomes.
    Biomed Pharmacother. 2025;184:117881.
    PubMed    
    Abstract available
    
    

53. LI Q, Shi X, Tang Y, Fu Y, et al
    Shared genes and relevant potential molecular linkages between COVID-19 and chronic thromboembolic pulmonary hypertension (CTEPH).
    J Thromb Thrombolysis. 2025 Feb 1. doi: 10.1007/s11239-025-03072.
    PubMed    
    Abstract available
    
    

54. DA COSTA RODRIGUES J, Gazarian C, Maillard J, Albu G, et al
    Emergency ECMO Deployment During Liver Transplantation in Portopulmonary Hypertension Patients.
    Am J Case Rep. 2025;26:e946268.
    PubMed    
    Abstract available
    
    

55. HASSELFELD K, Hysinger E, House M
    Preterm Infants With Bronchopulmonary Dysplasia and Pulmonary Hypertension.
    Neoreviews. 2025;26:e132-e140.
    PubMed    
    
    
    

56. ZHAO Z, Sang M, Li Q, Zhang H, et al
    Targeted FTO knockout in endothelial cells Boosts adhesion and lowers inflammatory infiltration to alleviate pulmonary arterial hypertension.
    Biochem Biophys Res Commun. 2025;749:151339.
    PubMed    
    Abstract available
    
    

57. TIAN XT, Peng ZY, Wu YS, Cao YY, et al
    Loss of Type 2 Bone Morphogenetic Protein Receptor Activates NOD-Like Receptor Family Protein 3/Gasdermin E-Mediated Pyroptosis in Pulmonary Arterial Hypertension.
    J Am Heart Assoc. 2025;14:e034726.
    PubMed    
    Abstract available
    
    

58. TAN W, Wang Y, Li M, Zhao C, et al
    A novel pyridine-2-one AMPK inhibitor: Discovery, mechanism, and in vivo evaluation in a hypoxic pulmonary arterial hypertension rat model.
    Eur J Med Chem. 2025;286:117266.
    PubMed    
    Abstract available
    
    

59. ALBIACH-DELGADO A, Pinilla-Gonzalez A, Cascant-Vilaplana MM, Solaz-Garcia A, et al
    The effect of inhaled nitric oxide treatment on biomarkers of oxidative/nitrosative damage to proteins and DNA/RNA.
    Free Radic Biol Med. 2025;228:350-359.
    PubMed    
    Abstract available
    
    

60. KUNICKI PK, Grymm MT, Pawinski T, Szulczyk D, et al
    A simple HPLC-UV method for monitoring therapeutic adherence in pulmonary arterial hypertension.
    J Chromatogr B Analyt Technol Biomed Life Sci. 2025;1252:124443.
    PubMed    
    Abstract available
    
    

61. KOPEC G, Skride A, Ereminiene E, Simkova I, et al
    Emerging therapies and new directions in the treatment of pulmonary arterial hypertension.
    Kardiol Pol. 2025;83:18-26.
    PubMed    
    Abstract available
    
    

62. XIE S, Zhao J, Zhang F, Li X, et al
    Dehydrodiisoeugenol inhibits PDGF-BB-induced proliferation and migration of human pulmonary artery smooth muscle cells via the mTOR/HIF1-alpha/HK2 signaling pathway.
    Toxicol Appl Pharmacol. 2025;495:117212.
    PubMed    
    Abstract available
    
    

63. THARWANI A, Minai O, Rao Y, Kim H, et al
    The minimally important difference in the six-minute walk test predicts clinical worsening in pulmonary arterial hypertension.
    Respir Med. 2025;237:107919.
    PubMed    
    Abstract available
    
    

64. PARK A, Brillhart A, Sethi S, Abramor B, et al
    Characteristics of Climbers with High Altitude Pulmonary Edema on Mount Aconcagua.
    Wilderness Environ Med. 2025;36:113-118.
    PubMed    
    Abstract available
    
    

65. WHITE RJ, Vizza D, Klok R, Harley J, et al
    Health-related quality of life and symptom concordance between patients and physicians in pulmonary arterial hypertension in the United States, Europe, and Japan.
    Respir Med. 2025;237:107869.
    PubMed    
    Abstract available
    
    

66. SUN H, Stockbridge N, Ivy DD, Clark J, et al
    Actigraphy Study Endpoints to Reduce Sample Size and Facilitate Drug Development for Pediatric Pulmonary Arterial Hypertension.
    J Pediatr. 2025;277:114383.
    PubMed    
    Abstract available
    
    

67. KUMAR KR, Ciociola EC, Skinner KR, Dixit GM, et al
    Pharmacoepidemiology of combination pulmonary vasodilator therapy in critically ill infants.
    Cardiol Young. 2025;35:93-101.
    PubMed    
    Abstract available
    
    

68. GAMI A, Jani VP, Mombeini H, Osgueritchian R, et al
    Prognostic Value of Echocardiographic Coupling Metrics in Systemic Sclerosis-Associated Pulmonary Vascular Disease.
    J Am Soc Echocardiogr. 2025;38:115-126.
    PubMed    
    Abstract available
    
    

69. VENET M, Malik A, Gold S, Zhang N, et al
    Impact of Right Ventricular Pressure Overload on Myocardial Stiffness Assessed by Natural Wave Imaging.
    JACC Cardiovasc Imaging. 2025;18:211-225.
    PubMed    
    Abstract available
    
    

70. CHIU SN, Tseng WC, Lu CW, Lin MT, et al
    Atrial flutter/fibrillation in adult congenital heart disease: Insights from a large Asian cohort.
    J Formos Med Assoc. 2025;124:126-132.
    PubMed    
    Abstract available
    
    

71. DAWES TJW, Woodham V, Sharkey E, McEwan A, et al
    Predicting Peri-Operative Cardiorespiratory Adverse Events in Children with Idiopathic Pulmonary Arterial Hypertension Undergoing Cardiac Catheterization Using Echocardiography: A Cohort Study.
    Pediatr Cardiol. 2025;46:475-484.
    PubMed    
    Abstract available
    
    

72. CHEN D, Yang J, Zhang T, Li X, et al
    Mechanistic Investigation of Calcium Channel Regulation-Associated Genes in Pulmonary Arterial Hypertension and Signatures for Diagnosis.
    Mol Biotechnol. 2025;67:1122-1136.
    PubMed    
    Abstract available
    
    

73. MUSCOGIURI E, Van Ballaer V, De Wever W, Di Dedda E, et al
    Uncommon Causes of Pulmonary Hypertension With Associated Cardiomyopathy: Computed Tomography and Magnetic Resonance Imaging of Cardiothoracic Manifestations.
    Echocardiography. 2025;42:e70103.
    PubMed    
    Abstract available
    
    

74. PITSIOU GG
    Treatment Approaches for Pulmonary Hypertension in Colombia: A Call to Action.
    Clin Respir J. 2025;19:e70062.
    PubMed    
    
    
    

75. SHI X, Ma X, Wang H, He X, et al
    Elevated serum levels of HIF-1alpha and VEGF as potential biomarkers in connective tissue disease-associated pulmonary arterial hypertension.
    Sci Rep. 2025;15:5410.
    PubMed    
    Abstract available
    
    

76. JARAMILLO C, Tabaza S, Ferguson E, Odisio E, et al
    Chronic thromboembolic pulmonary hypertension: Role of imaging in diagnosis and guiding the treatment.
    Clin Imaging. 2025;120:110430.
    PubMed    
    Abstract available
    
    

77. PRASAD RR, Kumar S, Zhang H, Li M, et al
    An intracellular complement system drives metabolic and proinflammatory reprogramming of vascular fibroblasts in pulmonary hypertension.
    JCI Insight. 2025 Feb 13:e184141. doi: 10.1172/jci.insight.184141.
    PubMed    
    Abstract available
    
    

78. DE VADDER A, Lemloh L, Bo B, Hale L, et al
    Bosentan as adjunctive therapy in neonates with congenital diaphragmatic hernia-associated pulmonary hypertension: a case series.
    Eur J Pediatr. 2025;184:198.
    PubMed    
    Abstract available
    
    

79. CONDIT PE, Hokanson JS, Balasubramaniam V, McCulley DJ, et al
    Risk Factors Associated With the Development of Late Pulmonary Artery Hypertension in Extremely Premature Infants.
    Pediatr Pulmonol. 2025;60:e27501.
    PubMed    
    Abstract available
    
    

80. KRAMER M, Rosenkranz S, Kramer T
    Depression in Pulmonary Hypertension: A Systematic Review of Clinical Outcomes, Treatment Interactions, and Emerging Technologies.
    J Clin Med. 2025;14:982.
    PubMed    
    Abstract available
    
    

81. NUCHE J, Ponz I, Sanchez Sanchez V, Bobeda J, et al
    Four-Dimensional Magnetic Resonance Pulmonary Flow Imaging for Assessing Pulmonary Vasculopathy in Patients with Postcapillary Pulmonary Hypertension.
    J Clin Med. 2025;14:929.
    PubMed    
    Abstract available
    
    

82. KURZYNA P, Witowicz A, Kedzierski P, Florczyk M, et al
    Sex-Specific Differences in Chronic Thromboembolic Pulmonary Hypertension Treated with Balloon Pulmonary Angioplasty.
    J Clin Med. 2025;14:899.
    PubMed    
    Abstract available
    
    

83. TARRAS ES, Singh I, Kreiger J, Joseph P, et al
    Exercise Pulmonary Hypertension and Beyond: Insights in Exercise Pathophysiology in Pulmonary Arterial Hypertension (PAH) from Invasive Cardiopulmonary Exercise Testing.
    J Clin Med. 2025;14:804.
    PubMed    
    Abstract available
    
    

84. WALI S, Hwej A, Welsh DJ, Wilson K, et al
    Connexin 43 Affects Pulmonary Artery Reactivity via Changes in Nitric Oxide Production and Influences Proliferative and Migratory Responses in Mouse Pulmonary Artery Fibroblasts.
    Int J Mol Sci. 2025;26:1280.
    PubMed    
    Abstract available
    
    

85. AHMADI A, Klein R, Gao D, Mielniczuk LM, et al
    Test-retest Assessment of Biventricular Myocardial Oxidative Metabolism and Perfusion in Pulmonary Hypertension Patients Using (11)C-acetate PET Imaging: A Pilot Study.
    Mol Imaging Biol. 2025 Feb 12. doi: 10.1007/s11307-025-01987.
    PubMed    
    Abstract available
    
    

86. GUO R, Mi L, Gao J, Yang Y, et al
    Natural killer cells are decreased in systemic sclerosis and have diagnostic value for pulmonary arterial hypertension incorporation.
    Sci Rep. 2025;15:5178.
    PubMed    
    Abstract available
    
    

87. HIBBERT B, Al-Abcha A
    Tricuspid Regurgitation and Pulmonary Hypertension: Putting the Cart Before the Horse.
    JACC Cardiovasc Interv. 2025;18:337-338.
    PubMed    
    
    
    

88. MOHAMED K, Bayoumi MAA, Rahmath MR, Elmalik EE, et al
    Severe pulmonary hypertension in a small-for-date neonate with skeletal dysplasia.
    BMJ Case Rep. 2025;18:e264256.
    PubMed    
    
    
    

89. VARELA CMR, Herrero IF, Melon NM, Cebada FS, et al
    Recurrent chronic thromboembolic pulmonary hypertension following balloon pulmonary angioplasty.
    Rev Esp Cardiol (Engl Ed). 2025 Feb 10:S1885-5857(25)00050.
    PubMed    
    
    
    

90. LICHTBLAU M, Lador F, Lechartier B, Ellegast JM, et al
    Pulmonary hypertension in the field of hematological and oncological diseases.
    Respiration. 2025 Feb 12:1-20. doi: 10.1159/000544126.
    PubMed    
    Abstract available
    
    

91. LYAPINA IN, Valieva ZS, Martynyuk TV
    [MD, Doctor of Medical Science, Head of the Department of Pulmonary Hypertension and Heart Diseases, Myasnikov Clinical Cardiology Institute].
    Kardiologiia. 2025;65:50-57.
    PubMed    
    Abstract available
    
    

92. ANDERSEN K, Larsson B, Bjorklund E, Mathilda Bergman E, et al
    [Chronic thromboembolic pulmonary hypertension].
    Lakartidningen. 2025;122:24034.
    PubMed    
    Abstract available
    
    

93. LEMAY SE, Mougin M, Sauvaget M, El Kabbout R, et al
    Unraveling AURKB as a potential therapeutic target in pulmonary hypertension using integrated transcriptomic analysis and pre-clinical studies.
    Cell Rep Med. 2025 Feb 3:101964. doi: 10.1016/j.xcrm.2025.101964.
    PubMed    
    Abstract available
    
    

94. GILLMEYER KR, Rinne ST, Rucci JM, Klings ES, et al
    Factors Associated with Referral to Expert Providers among Patients with Pulmonary Hypertension.
    Ann Am Thorac Soc. 2025 Feb 11. doi: 10.1513/AnnalsATS.202408.
    PubMed    
    Abstract available
    
    

95. QIU H, Chen J, Mei Z, Chen W, et al
    Dysregulated fatty acid metabolism in pericardiac adipose tissue of pulmonary hypertension due to left heart disease mice.
    FASEB J. 2025;39:e70355.
    PubMed    
    Abstract available
    
    

96. FU G, Qiu L, Wang J, Li S, et al
    Genome-wide characterization of circular RNAs in three rat models of pulmonary hypertension reveals distinct pathological patterns.
    BMC Genomics. 2025;26:127.
    PubMed    
    Abstract available
    
    

97. JIANG P, Huang H, Xie M, Liu Z, et al
    Single-cell characterization of the immune heterogeneity of pulmonary hypertension identifies novel targets for immunotherapy.
    BMC Immunol. 2025;26:5.
    PubMed    
    Abstract available
    
    

98. WANG YR, Yu Y, Liang ZS, Tong L, et al
    [Mechanism of L-perilla alcohol in intervening hypoxic pulmonary hypertension based on network pharmacology and experimental verification].
    Zhongguo Zhong Yao Za Zhi. 2025;50:209-217.
    PubMed    
    Abstract available
    
    

99. ZHAO L, Cunningham CM, Hong J, Agarwal S, et al
    A Cross-Species and Sex-Specific Meta-Analysis of Transcriptomic Studies of Pulmonary Hypertension.
    Am J Respir Cell Mol Biol. 2025 Feb 10. doi: 10.1165/rcmb.2024-0410.
    PubMed    
    Abstract available
    
    

100. 
     Retraction of: Exercise pulmonary hypertension by the mPAP/CO slope in primary mitral regurgitation.
     Eur Heart J Cardiovasc Imaging. 2025 Feb 10:jeaf016. doi: 10.1093.
     PubMed    
     
     
     

101. BACZYNSKI M, Weisz D, Thomas L, Fevrier S, et al
     Response to Inhaled Nitric Oxide and Mortality Among Very Preterm Neonates With Pulmonary Hypertension.
     JAMA Netw Open. 2025;8:e2458843.
     PubMed    
     Abstract available
     
     

102. CAHYONO A, Irwanto, Rahman MA, Widjiati W, et al
     Progression of pulmonary arterial hypertension: A study in model.
     Open Vet J. 2024;14:3498-3504.
     PubMed    
     Abstract available
     
     

103. ARCHAMBAULT JL, Hernandez TL, Nozik ES, Palmer C, et al
     Corrigendum to "Relationship Between Urine Serotonin and Persistent Pulmonary Hypertension of the Newborn". J Pediatr 2025; 276:114290.
     J Pediatr. 2025 Feb 8:114462. doi: 10.1016/j.jpeds.2025.114462.
     PubMed    
     
     
     

104. GAYEN S, Pescatore J, Bittner M, Naranjo M, et al
     Development of the pulmonary fibrosis, pulmonary vascular resistance, six minute walk distance, B-type natriuretic peptide, age (PVD-B65) risk score for patients with chronic lung disease and pulmonary hypertension.
     BMC Pulm Med. 2025;25:69.
     PubMed    
     Abstract available
     
     

105. LIU ZB, Zhu RR, Liu JL, Xu QR, et al
     NSD2 mediated H3K36me2 promotes pulmonary arterial hypertension by recruiting FOLR1 and metabolism reprogramming.
     Cell Signal. 2025;127:111594.
     PubMed    
     Abstract available
     
     

106. WANG Y, Su H, Lin X, Dai C, et al
     1,25-(OH)(2)D(3) improves SD rats high-altitude pulmonary edema by inhibiting ferroptosis and ferritinophagy in alveolar epithelial cells.
     J Steroid Biochem Mol Biol. 2025;247:106663.
     PubMed    
     Abstract available
     
     

107. SEIDEL LM, Thudium J, Smith C, Sapehia V, et al
     Death-associated protein kinase 1 prevents hypoxia-induced metabolic shift and pulmonary arterial smooth muscle cell proliferation in PAH.
     Cell Signal. 2025;127:111527.
     PubMed    
     Abstract available
     
     

108. RATWATTE S, Cordina RL, Baker D, Lau E, et al
     The importance of assessing and correcting hydration status prior to right heart catheterisation: a pilot study.
     Intern Med J. 2025;55:320-324.
     PubMed    
     Abstract available
     
     

109. NASER JA, Harada T, Reddy YN, Pislaru SV, et al
     Prevalence of HFpEF in Isolated Severe Secondary Tricuspid Regurgitation.
     JAMA Cardiol. 2025;10:182-187.
     PubMed    
     Abstract available
     
     

110. FU Z, Xie W, Gao Q, Zhang S, et al
     Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Disease: Success Rate and Complications among Different Patient Populations.
     Respiration. 2025;104:110-123.
     PubMed    
     Abstract available
     
     

111. MUKTHAPURAM S, Donaher A, Higano NS, Rowe JA, et al
     Magnetic Resonance Imaging Assessment of Pulmonary Vascularity in Preterm Infants with Bronchopulmonary Dysplasia.
     Neonatology. 2024 Jul 29:1-8. doi: 10.1159/000539545.
     PubMed    
     Abstract available
     
     

112. LI S, Chen Z, Li K, Zhang Z, et al
     The Impact of Valve Surgery on the Safety and Cardiac Function of Patients with Valvular Heart Disease Complicated by Pulmonary Arterial Hypertension.
     Altern Ther Health Med. 2025;31:76-83.
     PubMed    
     Abstract available
     
     

113. BYRNE A, Al-Hindawi Y, Plit M, Yeung L, et al
     The prevalence and pattern of post tuberculosis lung disease including pulmonary hypertension from an Australian TB service; a single-centre, retrospective cohort study.
     BMC Pulm Med. 2025;25:84.
     PubMed    
     Abstract available
     
     

114. CERESER L, Borghesi A, De Martino M, Nadarevic T, et al
     Machine-learning tool for classifying pulmonary hypertension via expert reader-provided CT features: An educational resource for non-dedicated radiologists.
     Eur J Radiol. 2025;185:111998.
     PubMed    
     Abstract available
     
     

115. MORGAN CE, Woolfall K, Aikman N, Gale C, et al
     Developing a Neonatal Pulmonary Hypertension Core Outcome Set (NeoPH COS)-A Study Protocol.
     Pulm Circ. 2025;15:e70052.
     PubMed    
     Abstract available
     
     

116. MACHADO-DUQUE M, Gaviria-Mendoza A, Valladales-Restrepo LF, Pacheco M, et al
     Treatment Patterns of Patients With Pulmonary Hypertension: A Descriptive Study in Colombia.
     Clin Respir J. 2025;19:e70063.
     PubMed    
     Abstract available
     
     

117. ANDERSEN S, Bjerre JV, Baekgaard K, Idorn L, et al
     Severe Precapillary Pulmonary Hypertension and Right Ventricular Failure After Hematopoietic Stem Cell Transplantation: Successful Outcomes With Aggressive Upfront Triple Therapy.
     Pediatr Blood Cancer. 2025 Feb 20:e31623. doi: 10.1002/pbc.31623.
     PubMed    
     
     
     

118. PATEL JN, Talon A, Hu C, Ma M, et al
     Descriptive Analysis of Oxygen Dependency and Hemodynamic Changes Following Pulmonary Thromboendarterectomy in Chronic Thromboembolic Pulmonary Hypertension Patients.
     Cureus. 2025;17:e77663.
     PubMed    
     Abstract available
     
     

119. FUJITA S, Shimokawahara H, Kanezawa M, Matsubara H, et al
     Case Report: Effective Management of Pulmonary Hypertension Associated With Takayasu Arteritis Through Both Immunosuppressive Therapy and Serial Balloon Pulmonary Angioplasty.
     Int J Rheum Dis. 2025;28:e70143.
     PubMed    
     
     
     

120. GAO L, Zhang S, Li S, Luo M, et al
     Association of insulin resistance surrogates with disease severity and adverse outcomes in chronic thromboembolic pulmonary hypertension: a multicenter cohort study.
     Cardiovasc Diabetol. 2025;24:82.
     PubMed    
     Abstract available
     
     

121. SCHULZE KM, Horn AG, Weber RE, Hageman KS, et al
     Bulk and regional diaphragm blood flow during chemical hyperpnea in pulmonary hypertensive rats.
     Respir Physiol Neurobiol. 2025 Feb 17:104414. doi: 10.1016/j.resp.2025.104414.
     PubMed    
     Abstract available
     
     

122. VARZIDEH F, Forzano I, Farroni E, Mone P, et al
     Macrophages Regulate Inflammatory Vascular Remodeling in Pulmonary Hypertension.
     Hypertension. 2025;82:460-462.
     PubMed    
     
     
     

123. FIORENTU G, Bernardinello N, Giulianelli G, Cocconcelli E, et al
     Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD): Back to the Future.
     Adv Ther. 2025 Feb 19. doi: 10.1007/s12325-025-03129.
     PubMed    
     Abstract available
     
     

124. HE C, Ji Y, Zhang Y, Ou J, et al
     Inhibition of Mettl3 by STM2457 and Loss of Macrophage Mettl3 Alleviate Pulmonary Hypertension and Right Heart Remodeling.
     Lung. 2025;203:34.
     PubMed    
     Abstract available
     
     

125. ZHANG R, Zhang Y, Li H, Zhang J, et al
     Single-cell transcriptomic analysis reveals distinct plasma cell populations in chronic thromboembolic pulmonary hypertension.
     J Thromb Haemost. 2025 Feb 16:S1538-7836(25)00105.
     PubMed    
     Abstract available
     
     

126. ROBBINS EW, Bradley K, Badesch DB, Burger C, et al
     Medication Non-Adherence in Patients with Pulmonary Arterial Hypertension: The Pulmonary Hypertension Association Registry (PHAR).
     Ann Am Thorac Soc. 2025 Feb 18. doi: 10.1513/AnnalsATS.202312-1083.
     PubMed    
     Abstract available
     
     

127. GERGES C, Jevnikar M, Brenot P, Savale L, et al
     Effect of Balloon Pulmonary Angioplasty and Riociguat on Right Ventricular Afterload and Function in CTEPH: Insights From the RACE Trial.
     Circ Cardiovasc Interv. 2025;18:e014785.
     PubMed    
     Abstract available
     
     

128. SMOOD B, Vasquez CR, Olia SE, Han JJ, et al
     Early Extracorporeal Membrane Oxygenation Initiation May Improve Outcomes in Select Patients With Primary Pulmonary Hypertension: An Extracorporeal Life Support Organization Registry Analysis.
     ASAIO J. 2025 Feb 18. doi: 10.1097/MAT.0000000000002390.
     PubMed    
     Abstract available
     
     

129. SCALONE EJ, Woodruff AG, Saha AK, Wright JM, et al
     Inhaled Epoprostenol in Children With Pediatric Acute Respiratory Distress Syndrome: A Single-Center Retrospective Study.
     Pediatr Pulmonol. 2025;60:e71010.
     PubMed    
     Abstract available
     
     

130. PACHE-WANNAZ L, Voicu C, Boillat L, Sekarski N, et al
     Case Report: severe pulmonary hypertension in a child with micronutrient deficiency.
     Front Pediatr. 2025;13:1478889.
     PubMed    
     Abstract available
     
     

131. LI HF, Li XY, Sun YQ, Zhi ZY, et al
     The Role of Ion Channels in Pulmonary Hypertension: A Review.
     Pulm Circ. 2025;15:e70050.
     PubMed    
     Abstract available
     
     

132. CHEN J, Chen X, Agrawal V, Moore CS, et al
     Estrogen and Cyp1b1 Regulate Ppargamma in Pulmonary Hypertension Through a Ubiquitin-Dependent Mechanism.
     Pulm Circ. 2025;15:e70054.
     PubMed    
     Abstract available
     
     

133. WANG H, Li L, Zhou G, Wang L, et al
     RPL39 Was Associated With Sex Differences in Pulmonary Arterial Hypertension.
     Can Respir J. 2025;2025:7139235.
     PubMed    
     Abstract available
     
     

134. PAMUKCU E, Kaya MO
     Meta-Analysis of Real-World Clinical Practice to Assess the Effectiveness of Riociguat in Treating Chronic Thromboembolic Pulmonary Hypertension.
     J Clin Hypertens (Greenwich). 2025;27:e70015.
     PubMed    
     Abstract available
     
     

135. GHILARDI S, Sala G, Locatelli C, Pravettoni D, et al
     Echocardiographic Changes Related to Pulmonary Hypertension in Preweaned Dairy Calves With Bronchopneumonia: A Case-Control Study in Commercial Dairy Farms.
     J Vet Intern Med. 2025;39:e70020.
     PubMed    
     Abstract available
     
     

136. LI H, Liu Y, Shi X, Luo Y, et al
     SP1/ADAM10/DRP1 axis links intercellular communication between smooth muscle cells and endothelial cells under hypoxia pulmonary hypertension.
     Biochim Biophys Acta Mol Basis Dis. 2025;1871:167720.
     PubMed    
     Abstract available
     
     

137. WANG P, Zhang X, Yao M, Li J, et al
     Targeting high mobility group protein B2 exerts antiproliferative effects in hypoxic pulmonary hypertension by modulating miR-21.
     Toxicol Appl Pharmacol. 2025;497:117265.
     PubMed    
     Abstract available
     
     

138. MENEZES TCF, Lee MH, Fonseca Balladares DC, Nolan K, et al
     Skeletal Muscle Pathology in Pulmonary Arterial Hypertension and Its Contribution to Exercise Intolerance.
     J Am Heart Assoc. 2025;14:e036952.
     PubMed    
     Abstract available
     
     

139. ROH DE, Park NR, Choi BG, Kang Y, et al
     TGFBI regulates pulmonary vascular remodeling through endothelial-to-mesenchymal transition in pulmonary arterial hypertension.
     Biochem Biophys Res Commun. 2025;751:151435.
     PubMed    
     Abstract available
     
     

140. COSTELLE A, Lu J, Leewiwatwong S, Westerhof B, et al
     Combining hyperpolarized (129)Xe MR imaging and spectroscopy to noninvasively estimate pulmonary vascular resistance.
     J Appl Physiol (1985). 2025;138:623-633.
     PubMed    
     Abstract available
     
     

141. KLOUDA T, Kim Y, Baek SH, Bhaumik M, et al
     Specialized pericyte subtypes in the pulmonary capillaries.
     EMBO J. 2025;44:1074-1106.
     PubMed    
     Abstract available
     
     

142. CHEN X, Li L, Deng Y, Liao J, et al
     Inhibition of glutaminase 1 reduces M1 macrophage polarization to protect against monocrotaline-induced pulmonary arterial hypertension.
     Immunol Lett. 2025;272:106974.
     PubMed    
     Abstract available
     
     

143. AIT-OUDHIA S, Jaworowicz D, Hu Z, Gaurav M, et al
     Population Pharmacokinetic/Pharmacodynamic and Exposure-Response Modeling Analyses of Sotatercept in Healthy Participants and Patients with Pulmonary Arterial Hypertension.
     Clin Pharmacol Ther. 2025;117:798-807.
     PubMed    
     Abstract available
     
     

144. STONE JN, Kuebel DJ, Guido MR, Elwing JM, et al
     Dual prostacyclin infusions: A case report of a patient symptom-driven transition from high-dose intravenous epoprostenol to subcutaneous treprostinil for the treatment of pulmonary arterial hypertension.
     Am J Health Syst Pharm. 2025;82:e256-e261.
     PubMed    
     Abstract available
     
     

145. LV X, Li J, Wei R, Meng L, et al
     Ethyl pyruvate alleviates pulmonary arterial hypertension via PI3K-Akt signaling.
     Mol Cell Biochem. 2025;480:1045-1054.
     PubMed    
     Abstract available
     
     

146. TOMA M, Savonitto G, Lombardi CM, Airo E, et al
     Frequency, characteristics and risk assessment of pulmonary arterial hypertension with a left heart disease phenotype.
     Clin Res Cardiol. 2025;114:215-226.
     PubMed    
     Abstract available
     
     

147. SEELEMANN ER, Panchakshari S, Labana PK, Wolverton MM, et al
     Sexual dimorphism in right ventricular adaptation to pressure overload involves differential angiogenic response.
     Am J Physiol Heart Circ Physiol. 2025;328:H496-H508.
     PubMed    
     Abstract available
     
     

148. ADAO R, Barreira B, Paternoster E, Morales-Cano D, et al
     Vitamin D as an add-on therapy to phosphodiesterase-5 inhibitor in experimental pulmonary arterial hypertension.
     Am J Physiol Lung Cell Mol Physiol. 2025;328:L253-L259.
     PubMed    
     Abstract available
     
     

149. DEL GALDO F, Lescoat A, Conaghan PG, Bertoldo E, et al
     EULAR recommendations for the treatment of systemic sclerosis: 2023 update.
     Ann Rheum Dis. 2025;84:29-40.
     PubMed    
     Abstract available
     
     

150. LANGLEBEN D, Lesenko L, Fox BD, Eintracht S, et al
     Ineffectiveness of Sotatercept Therapy in a Patient With Heritable Pulmonary Arterial Hypertension Associated With a Previously Unreported Missense Variant in GDF2, the Gene for Bone Morphogenic Protein-9.
     Chest. 2025;167:e37-e39.
     PubMed    
     Abstract available
     
     

151. MORRIS TA
     Chronic Thromboembolism Phenotypes Aside From Pulmonary Hypertension: "CTE(X)".
     Chest. 2025;167:322-323.
     PubMed    
     
     
     

152. D'ALTO M, Guazzi M
     Unlocking the Hidden Pearls of Using Tricuspid Annulus Plane Systolic Excursion on Pulmonary Arterial Systolic Pressure Ratio in the Prognostic Assessment of Suspected But Unconfirmed or Mild Pulmonary Hypertension.
     Chest. 2025;167:319-321.
     PubMed    
     
     
     

153. PLOEGSTRA MJ, Ferreira RJ, Lokhorst C, Gouwy E, et al
     Physical Activity Measured by Hip-Anchored Accelerometry in Pediatric Pulmonary Hypertension: Association with Disease Severity & Estimation of Minimal Important Differences.
     Chest. 2025 Feb 8:S0012-3692(25)00156-4. doi: 10.1016/j.chest.2025.
     PubMed    
     Abstract available
     
     

154. JOHN T, Avian A, John N, Eger A, et al
     Prognostic Relevance of Tricuspid Annular Plane Systolic Excursion to Systolic Pulmonary Arterial Pressure Ratio and Its Association With Exercise Hemodynamics in Patients With Normal or Mildly Elevated Resting Pulmonary Arterial Pressure.
     Chest. 2025;167:573-584.
     PubMed    
     Abstract available
     
     

155. INSEL M, El Aini T, Woodhead G, Wig R, et al
     Post Pulmonary Embolism Phenotypes Described by Invasive Cardiopulmonary Exercise Testing.
     Chest. 2024 Sep 3:S0012-3692(24)05134-1. doi: 10.1016/j.chest.2024.
     PubMed    
     Abstract available
     
     

156. ALENEZI F, Costelle A, Sharma P, Barrett M, et al
     (129)Xenon MR Imaging and Spectroscopy Detects Response to Therapy in Pulmonary Hypertension.
     Eur Respir J. 2025 Jan 30:2401651. doi: 10.1183/13993003.01651-2024.
     PubMed    
     
     
     

157. WRIGHT SP, Karvasarki E, Buchan TA, Gurtu V, et al
     Contemporary pulmonary hypertension hemodynamic definitions stratify mortality risk in candidates for advanced heart failure therapies.
     Eur Respir J. 2025 Jan 30:2401640. doi: 10.1183/13993003.01640-2024.
     PubMed    
     
     
     

158. WANG S, Zhuo D, Lin J, Zhang C, et al
     Key Genes and Biological Pathways in Pulmonary Arterial Hypertension Related to Endoplasmic Reticulum Stress Identified by Bioinformatics.
     J Cardiovasc Pharmacol. 2025;85:108-119.
     PubMed    
     Abstract available
     
     

159. ALSULAYYIM AS, Alasmari AM, Price LC, McCabe C, et al
     Dietary nitrate supplementation enhances exercise capacity in WHO Group 3 pulmonary hypertension: a double-blind, placebo-controlled, randomised crossover study (EDEN-OX2).
     Thorax. 2025 Feb 8:thorax-2024-222019. doi: 10.1136/thorax-2024-222019.
     PubMed    
     Abstract available
     
     

160. GHAZAIEAN M, Darvishi-Khezri H, Najafi B, Karami H, et al
     Global prevalence of elevated estimated pulmonary artery systolic pressure in clinically stable children and adults with sickle cell disease: A systematic review and meta-analysis.
     PLoS One. 2025;20:e0318751.
     PubMed    
     Abstract available
     
     

161. YOON DW, Yoon YE, Hwang IC, Lee W, et al
     CT imaging biomarkers to predict severity and prognosis of pulmonary hypertension.
     PLoS One. 2025;20:e0313235.
     PubMed    
     Abstract available
     
     

162. MARTINEZ-PUIG P, Baez-Gutierrez N, Rodriguez-Ramallo H, Abdelkader-Martin L, et al
     Systematic evaluation of subgroup analyses of inhaled treprostinil in pulmonary hypertension due to interstitial lung disease.
     PLoS One. 2025;20:e0318739.
     PubMed    
     Abstract available